14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
LBRX vs LMRI: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, LB Pharmaceuticals Inc (LBRX) is the stronger overall head-to-head candidate over LMRI (LMRI) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). LBRX carries a Unified Composite Score of 38.2/100 (SELL) at $38.85 (N/M Forward P/E, 0.0% operating margin), whereas LMRI carries 32.1/100 (SELL) at $14.26 (N/M Forward P/E, N/A operating margin).
Defensive Composite Rating Caution: Although LBRX compares more favorably head-to-head, both LBRX (38.2/100 SELL) and LMRI (32.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: LBRX is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 43.8); meanwhile LMRI trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LBRX vs LMRI. Trailing 12-month operating profitability (LBRX 0.0% vs LMRI N/A) and valuation multiples (LBRX N/M vs LMRI N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ LBRX vs LMRI Key Questions & Quantitative Answers
As of Nov 20, 2026, LB Pharmaceuticals Inc (LBRX) is the stronger overall head-to-head candidate over LMRI (LMRI) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). LBRX carries a Unified Composite Score of 38.2/100 (SELL) at $38.85 (N/M Forward P/E, 0.0% operating margin), whereas LMRI carries 32.1/100 (SELL) at $14.26 (N/M Forward P/E, N/A operating margin). Defensive Composite Rating Caution: Although LBRX compares more favorably head-to-head, both LBRX (38.2/100 SELL) and LMRI (32.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: LBRX is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 43.8); meanwhile LMRI trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
LBRX leads the Growth & Scale pillar: LBRX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with LMRI at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, LBRX generates N/A in USD-normalized revenue versus N/A for LMRI. In operating R&D and SG&A reinvestment, LBRX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LMRI.
LBRX and LMRI trade at balanced relative valuation multiples. LBRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas LMRI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LBRX (-38.8% ROE) versus LMRI (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, LBRX carries 78.9% implied volatility (4th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.07β · 60% Vol realized risk). By comparison, LMRI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.22β · 85% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.